131 related articles for article (PubMed ID: 16826116)
1. Vascular endothelial growth factor expression in osteosarcoma.
Charity RM; Foukas AF; Deshmukh NS; Grimer RJ
Clin Orthop Relat Res; 2006 Jul; 448():193-8. PubMed ID: 16826116
[TBL] [Abstract][Full Text] [Related]
2. Vascular endothelial growth factor expression in untreated osteosarcoma is predictive of pulmonary metastasis and poor prognosis.
Kaya M; Wada T; Akatsuka T; Kawaguchi S; Nagoya S; Shindoh M; Higashino F; Mezawa F; Okada F; Ishii S
Clin Cancer Res; 2000 Feb; 6(2):572-7. PubMed ID: 10690541
[TBL] [Abstract][Full Text] [Related]
3. Ezrin expression predicts survival in stage IIB osteosarcomas.
Kim MS; Song WS; Cho WH; Lee SY; Jeon DG
Clin Orthop Relat Res; 2007 Jun; 459():229-36. PubMed ID: 17353802
[TBL] [Abstract][Full Text] [Related]
4. Expression of osteopontin and vascular endothelial growth factor in benign and malignant bone tumors.
Sulzbacher I; Birner P; Trieb K; Lang S; Chott A
Virchows Arch; 2002 Oct; 441(4):345-9. PubMed ID: 12404059
[TBL] [Abstract][Full Text] [Related]
5. Expression of vascular endothelial growth factor-C and its receptor in osteosarcomas.
Park HR; Min K; Kim HS; Jung WW; Park YK
Pathol Res Pract; 2008; 204(8):575-82. PubMed ID: 18440723
[TBL] [Abstract][Full Text] [Related]
6. Expression of platelet-derived growth factor-AA is associated with tumor progression in osteosarcoma.
Sulzbacher I; Birner P; Trieb K; Träxler M; Lang S; Chott A
Mod Pathol; 2003 Jan; 16(1):66-71. PubMed ID: 12527715
[TBL] [Abstract][Full Text] [Related]
7. Noninvasive imaging surrogate of angiogenesis in osteosarcoma.
Bajpai J; Gamanagatti S; Sharma MC; Kumar R; Vishnubhatla S; Khan SA; Rastogi S; Malhotra A; Bakhshi S
Pediatr Blood Cancer; 2010 Apr; 54(4):526-31. PubMed ID: 19890899
[TBL] [Abstract][Full Text] [Related]
8. A prognostic evaluation of vascular endothelial growth factor in children and young adults with osteosarcoma.
Ługowska I; Woźniak W; Klepacka T; Michalak E; Szamotulska K
Pediatr Blood Cancer; 2011 Jul; 57(1):63-8. PubMed ID: 21416580
[TBL] [Abstract][Full Text] [Related]
9. Expression of transforming growth factor-beta (TGF-beta) isoforms in osteosarcomas: TGF-beta3 is related to disease progression.
Kloen P; Gebhardt MC; Perez-Atayde A; Rosenberg AE; Springfield DS; Gold LI; Mankin HJ
Cancer; 1997 Dec; 80(12):2230-9. PubMed ID: 9404699
[TBL] [Abstract][Full Text] [Related]
10. The level of vascular endothelial growth factor as a predictor of a poor prognosis in osteosarcoma.
Kaya M; Wada T; Nagoya S; Sasaki M; Matsumura T; Yamashita T
J Bone Joint Surg Br; 2009 Jun; 91(6):784-8. PubMed ID: 19483233
[TBL] [Abstract][Full Text] [Related]
11. P16 expression predicts necrotic response among patients with osteosarcoma receiving neoadjuvant chemotherapy.
Borys D; Canter RJ; Hoch B; Martinez SR; Tamurian RM; Murphy B; Bishop JW; Horvai A
Hum Pathol; 2012 Nov; 43(11):1948-54. PubMed ID: 22578565
[TBL] [Abstract][Full Text] [Related]
12. Epidermal growth factor receptor expression in high-grade osteosarcomas is associated with a good clinical outcome.
Kersting C; Gebert C; Agelopoulos K; Schmidt H; van Diest PJ; Juergens H; Winkelmann W; Kevric M; Gosheger G; Brandt B; Bielack S; Buerger H
Clin Cancer Res; 2007 May; 13(10):2998-3005. PubMed ID: 17505002
[TBL] [Abstract][Full Text] [Related]
13. Growth patterns of osteosarcoma predict patient survival.
Kim MS; Lee SY; Cho WH; Song WS; Koh JS; Lee JA; Yoo JY; Shin DS; Jeon DG
Arch Orthop Trauma Surg; 2009 Sep; 129(9):1189-96. PubMed ID: 18682966
[TBL] [Abstract][Full Text] [Related]
14. RANKL expression is related to treatment outcome of patients with localized, high-grade osteosarcoma.
Lee JA; Jung JS; Kim DH; Lim JS; Kim MS; Kong CB; Song WS; Cho WH; Jeon DG; Lee SY; Koh JS
Pediatr Blood Cancer; 2011 May; 56(5):738-43. PubMed ID: 21370405
[TBL] [Abstract][Full Text] [Related]
15. A preliminary investigation of Beta-hCG expression in patients with osteosarcoma.
Masrouha KZ; Khattab R; Tawil A; Abdallah A; Saghieh S; Haidar R; Abboud M; Khoury NJ
J Bone Joint Surg Br; 2012 Mar; 94(3):419-24. PubMed ID: 22371553
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of HLA-DR expression and T-lymphocyte infiltration in osteosarcoma.
Trieb K; Lechleitner T; Lang S; Windhager R; Kotz R; Dirnhofer S
Pathol Res Pract; 1998; 194(10):679-84. PubMed ID: 9820863
[TBL] [Abstract][Full Text] [Related]
17. Prognostic significance of immunohistochemical expression of ezrin in non-metastatic high-grade osteosarcoma.
Ferrari S; Zanella L; Alberghini M; Palmerini E; Staals E; Bacchini P
Pediatr Blood Cancer; 2008 Apr; 50(4):752-6. PubMed ID: 17886294
[TBL] [Abstract][Full Text] [Related]
18. Interferon-α/β receptor as a prognostic marker in osteosarcoma.
Kubo T; Shimose S; Matsuo T; Fujimori J; Arihiro K; Ochi M
J Bone Joint Surg Am; 2011 Mar; 93(6):519-26. PubMed ID: 21411701
[TBL] [Abstract][Full Text] [Related]
19. Expression of platelet-derived growth factor-alpha receptor in human osteosarcoma is not a predictor of outcome.
Sulzbacher I; Birner P; Dominkus M; Pichlhofer B; Mazal PR
Pathology; 2010 Dec; 42(7):664-8. PubMed ID: 21080877
[TBL] [Abstract][Full Text] [Related]
20. Prognostic significance of vascular endothelial growth factor and cyclooxygenase 2 expression in patients receiving preoperative chemoradiation for esophageal cancer.
Kulke MH; Odze RD; Mueller JD; Wang H; Redston M; Bertagnolli MM
J Thorac Cardiovasc Surg; 2004 Jun; 127(6):1579-86. PubMed ID: 15173710
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]